Non-immunogenic recombinant staphylokinase versus alteplase for patients with massive pulmonary embolism: a randomized open-label, multicenter, parallel-group, non-inferiority trial, FORPE
- 23 October 2024
- journal article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 23 (2) , 657-667
Abstract
No abstract availableKeywords
Funding Information
- Ministry of Science and Higher Education of the Russian Federation
- Ministry of Science and Higher Education of the Russian Federation (075-15-2022-305)
This publication has 20 references indexed in Scilit:
- Clinical profile and outcome of isolated pulmonary embolism: a systematic review and meta-analysiseClinicalMedicine, 2023
- Extended Mechanism of the Plasminogen Activator Staphylokinase Revealed by Global Kinetic Analysis: 1000-fold Higher Catalytic Activity than That of Clinically Used AlteplaseACS Catalysis, 2022
- Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4·5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trialThe Lancet Neurology, 2021
- 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)European Heart Journal, 2019
- Short- and Long-term Mortality Risk After Acute Pulmonary EmbolismCurrent Cardiology Reports, 2018
- Fibrinolysis for Patients with Intermediate-Risk Pulmonary EmbolismNew England Journal of Medicine, 2014
- Heparin plus Alteplase Compared with Heparin Alone in Patients with Submassive Pulmonary EmbolismNew England Journal of Medicine, 2002
- Third-generation thrombolytic drugsThe American Journal of Medicine, 2000
- Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agentNature Medicine, 1998
- Role of Staphylokinase in the Acquisition of Plasmin(ogen)-Dependent Enzymatic Activity by StaphylococciThe Journal of Infectious Diseases, 1996